type="text/javascript">

Should the FDA be approving more biosimilars?

FDAnew

Should the FDA be approving more biosimilars? That’s a question that some analysts are asking. Since the FDA approved Sandoz’s Zarxio in March of 2015, there has not been another approval. The FDA has accepted applications for several biosimilar products, but the process has moved slower than some would like.

Read the source article at Welcome to AIS Health

About the Author

Related Posts

Leave a Reply

*